Community acquired pneumonia in childrenBMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j686 (Published 02 March 2017) Cite this as: BMJ 2017;356:j686
- Iram J Haq, registrar and clinical research associate in paediatric respiratory medicine1 2,
- Alexandra C Battersby, registrar in paediatric immunology and infectious diseases3,
- Katherine Eastham, consultant paediatrician4,
- Michael McKean, consultant in paediatric respiratory medicine and clinical director2
- 1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
- 2Department of Paediatric Respiratory Medicine, Great North Children’s Hospital, Newcastle upon Tyne
- 3Department of Paediatric Immunology and Infectious Diseases, Great North Children’s Hospital, Newcastle upon Tyne
- 4Department of Paediatrics, Sunderland Royal Hospital, Sunderland, UK
Correspondence to: I J Haq email@example.com
What you need to know
Introduction of the pneumococcal conjugate vaccine has significantly reduced rates of community acquired pneumonia (CAP) in the developed world
Clinical assessment requires careful evaluation of clinical features, severity, and evidence of complications
Children with mild to moderate symptoms can be managed in the community
Recommended empirical first line treatment is oral amoxicillin. Intravenous antibiotics are indicated in children who cannot tolerate oral medicines or have septicaemia or complications
Patients should be reviewed 48 hours after starting treatment to monitor response and for evidence of complications
In 2015, community acquired pneumonia (CAP) accounted for 15% of deaths in children under 5 years old globally and 922 000 deaths globally in children of all ages.1 It is defined as a clinical diagnosis of pneumonia caused by a community acquired infection in a previously healthy child.2 Clinical assessment can be challenging; symptoms vary with age and can be non-specific in young children, and aetiology is often unknown at presentation.
This article will provide an update on CAP management in otherwise healthy children outside the neonatal period and summarises recommendations from the British Thoracic Society guidelines for UK practice.2 Similar international guidelines, including the World Health Organisation and Infectious Diseases Society of America guidelines, have some treatment variations, probably dependent on drug availability, cost, and antibiotic resistance patterns.34
How common is CAP?
Around 14.4 per 10 000 children aged over 5 years and 33.8 per 10 000 under 5 years are diagnosed with CAP annually in European hospitals.56 CAP is more common in the developing world, estimated at 0.28 episodes per child per year and accounting for 95% of all cases.7 Incidence data varies and may be explained by variation in diagnostic criteria. A bias exists towards hospital based studies, which potentially underestimates overall incidence. Children aged 5-16 years are underrepresented in the literature, making assessment of CAP prevalence in this group difficult.
In otherwise healthy children, those less than 5 years old are at greatest risk. Boys have a higher incidence across all ages.5 Other risk factors include prematurity, immunodeficiency, chronic respiratory disease, and neurodisability.
What causes CAP?
Defining causative organisms is a challenge. Clinical and radiological features do not reliably distinguish between viral and bacterial aetiology, and obtaining cultures from the lower respiratory tract of young children is tricky. More specific but invasive investigations such as pleural aspiration are infrequently indicated and reserved for severe cases. Blood cultures are rarely performed in patients managed in the community, and hospitalised patients demonstrate a poor yield.8
Nasopharyngeal secretions are easily obtainable, and the application of more sensitive techniques such as polymerase chain reaction (PCR) has resulted in pathogen identification in 65-83% of reported cases.9 Although rapid viral detection is now available with multiplex PCR techniques, differentiating bacterial superinfection from colonisation remains difficult.10
CAP aetiology varies with age (table 1⇓). Respiratory viruses are common, particularly in infants, accounting for 30-67% of hospitalised cases. Respiratory syncytial virus accounts for 30% of viral aetiology. Other viruses include parainfluenza, influenza, and human metapneumovirus.111213Streptococcus pneumoniae is the commonest bacterial cause across all ages, accounting for 30-40% of cases.913 Other bacterial causes include group A streptococcus and, in infants, group B streptococcus. Staphylococcal aureus is associated with round pneumonia, a well defined round area of consolidation visible on chest x ray. Despite a well established vaccination programme, Haemophilus influenza remains prevalent in the UK, albeit at lower rates.13Mycoplasma pneumoniae accounts for up to a third of all cases and is a common cause of atypical CAP.1415
Less common pathogens are often related to an underlying health problem—for example, fungi in an immunocompromised child. Burkhodheria cepacia, Aspergillus fumigatus, and Pseudomonas aeruginosa are associated with primary immunodeficiency and cystic fibrosis.16 Consider aspiration pneumonia in high risk children or if the history is suggestive.
If there has been recent foreign travel, unusual organisms associated with the travel destination and variations with antibiotic resistance are important considerations. Consider atypical organisms if treatment fails.
How is CAP assessed?
Figure 1⇓ summarises the approach for assessment and management of CAP. Assess the likelihood and severity of CAP by measuring fever, tachypnoea, cough, breathlessness, chest wall recession, and chest pain. Respiratory rate and dyspnoea are useful measures of severity and predict oxygen requirement.217 A UK prospective study investigating children with radiologically defined CAP found respiratory rate to be positively correlated with reduced oxygen saturations in children of all ages and dyspnoea in children over 1 year old.17 Increased work of breathing is associated with radiological changes.1819
It is difficult to distinguish clinically between bacterial and viral aetiologies. Consider bacterial pneumonia in children presenting with persistent or recurrent fever ≥38.5°C over the preceding 24-48 hours with chest wall recession and tachypnoea.2 Fever and tachypnoea are early features of pneumococcal pneumonia. Cough is not always apparent or required for diagnosis, and may be absent in the early stages of illness. Mycoplasma pneumonia presents with cough and chest pain and is often associated with wheeze, general malaise, arthralgia, sore throat, and headache.
Clinical features vary with age. Local variations in CAP management and definitions can be challenging when comparing studies. Often a combination of clinical signs, rather than individual features, leads to a clinical diagnosis and helps assess severity.
Table 2⇓ lists disease severity markers to help aid management. Mild to moderate severity confers a low risk of complications. Previously well children with only mild symptoms who present directly to community or acute secondary services can be managed safely in the community. Children with severe symptoms require secondary care referral for urgent assessment and may require admission to paediatric intensive care (box 1). Children who present with mild symptoms but have red flag features (box 2) may require secondary care management and need careful assessment.
Box 1: British Thoracic Society criteria for referral to paediatric intensive care2
Indications for referral
Development of respiratory failure requiring assisted ventilation
Pneumonia complicated by septicaemia
Failure to maintain oxygen saturations >92% with FiO2 60%
Clinical features of shock
Increasing respiratory and heart rates with severe respiratory distress and exhaustion, with or without raised pCO2
Recurrent apnoea or slow irregular breathing
British Thoracic Society admission criteria are similar to those of international guidelines in similar resource settings.4
FiO2 = fraction of inspired oxygen. pCO2 = partial pressure of carbon dioxide.
Box 2: Red flag features for community acquired pneumonia (CAP)
History of underlying comorbidities, including
Disorders of mucus clearance (such as cystic fibrosis)
Congenital heart disease
Severe cerebral palsy
Relevant medical history
History of severe pneumonia (inpatient stay requiring oxygen, paediatric intensive care admission, complications of CAP (such as lung abscess, effusion, empyema)
Assessment in the community
Focus the examination on defining severity and identify children with underlying conditions who are at increased risk. Hypoxaemia increases mortality risk, and oxygen saturations <95% in room air are a key indicator for hospital assessment.20
Assessment in hospital
All children require pulse oximetry. Level of C reactive protein is not useful to differentiate viral and bacterial causes, but it can guide investigation and management of CAP complicated by effusions, empyema, or necrosis.2 Urinary pneumococcal antigen detection has a high sensitivity but very low specificity.21 If it is available, consider using it as a negative predictor.2
Avoid routine chest radiography in children requiring hospital admission.2 Radiographic appearance correlates poorly with clinical signs and outcome, and there is high inter-observer variability in interpretation.2223 Consider radiography in severe cases or where complications such as effusion or empyema are suspected (fig 2⇓).
Investigations recommended by the British Thoracic Society for complicated or severe CAP are summarised in box 3.2
Box 3: British Thoracic Society recommended investigations for complicated or severe community acquired pneumonia (CAP)2
Bloods (full blood count, urea and electrolytes, C reactive protein, blood culture, anti-streptolysin O titre, serology for viruses, Mycoplasma pneumoniae and Chlamydia pneumoniae, atypical CAP screen)
Nasopharyngeal secretions and swabs for viral PCR or immunofluorescence detection
Chest x ray to assess for effusion or empyema
Consider pleural fluid for microscopy, culture (including tuberculosis), pneumococcal antigen for PCR, biochemistry, and cytology (if aspiration required)
PCR = polymerase chain reaction.
How is CAP managed?
Children with clinical features consistent with CAP require antibiotics (box 4). CAP in a fully vaccinated child less than 2 years old (who has received the pneumococcal vaccine) with mild symptoms is unlikely to be bacterial, and antibiotics are not required unless symptoms become more severe.2
Box 4: British Thoracic Society recommendations for antibiotic selection in community acquired pneumonia (CAP)2
Preferred route of administration
Oral antibiotics are safe and effective for children even with severe CAP
Use intravenous antibiotics in children who:
Are unable to tolerate oral fluids (such as because of vomiting) or
Have signs of septicaemia or complicated pneumonia
Amoxicillin is first line therapy (use macrolides as first line in penicillin allergy)
Macrolides can be added at any age if there is no response to first line therapy
Macrolides should be used if Mycoplasma or Chlamydia pneumoniae are suspected or if disease is severe
Co-amoxiclav is recommended for pneumonia associated with influenza
Intravenous antibiotic treatment with amoxicillin, co-amoxiclav, cefuroxime, cefotaxime, or ceftriaxone is recommended for severe pneumonia
British Thoracic Society guidelines recommend amoxicillin as first line treatment.2 Consider adding a macrolide if there is no improvement or resolution of symptoms after 48 hours. Macrolides are recommended instead of amoxicillin as first line treatment if the child is allergic to penicillin. Dual treatment with amoxicillin and a macrolide may be considered for suspected mycoplasma pneumonia.
Antibiotic resistance is a global issue. Penicillin and macrolide resistance of Streptococcus pneumoniae is low in the UK compared with mainland Europe.2 Second or third line treatment may be required to cover resistant pneumococcal strains or children who have recently travelled to mainland Europe. There is evidence of increasing macrolide resistance of group A streptococcus, with varying rates worldwide.24
Several large randomised controlled trials, including the UK PIVOT trial, have shown that oral amoxicillin produces outcomes equivalent to those achieved with parenteral penicillin.252627 This was confirmed by a Cochrane review of children hospitalised with severe CAP.28 However, a UK audit of children requiring hospital admission found that co-amoxiclav was most commonly used.29 This is probably explained by variations in clinical custom. Amoxicillin is safe to administer orally if tolerated, even in cases of severe CAP. Its treatment efficacy is similar to co-amoxiclav but is better tolerated and more cost effective.2
In the absence of guidance for optimal treatment duration, empirical treatment is generally for 7-10 days. The UK CAPIT study will investigate the optimum treatment dose and duration.30
Supportive therapies and advice for care givers
For children managed in the community with mild to moderate symptoms, provide safety net advice on signs of deterioration, dehydration, and complications. Offer written information, if available, regarding fever management and what to watch out for. Ask the parents or carers to seek further advice if fever persists or symptoms deteriorate despite 48 hours of antibiotic treatment.
In secondary care, children with oxygen saturations <92% in room air require supplemental oxygen to maintain >95% saturation. Oxygen can be administered via face mask, nasal cannulae, or head box (a device that surrounds the head to deliver humidified oxygen to babies). Method of delivery depends on the clinical condition, required volume of inspired oxygen, and practical considerations such as age and feeding. There is no evidence to suggest that any method is superior to others.2
Hydration can become compromised in severe CAP due to breathlessness, fatigue, and vomiting. Nasogastric feeds can maintain hydration, but if they are not tolerated because of vomiting or severe illness, intravenous fluid replacement may be required, with daily electrolyte monitoring for sodium depletion or syndrome of inappropriate antidiuretic hormone secretion.
Clinical trials have not shown any benefit from physiotherapy on radiological resolution, length of hospital stay, or symptom improvement.3132 This may not be true during recovery for children with underlying respiratory diseases and impaired mucus clearance.
Empyema (pus in the pleural space) is the most common complication.33Table 3⇓ summarises the clinical features that should arouse suspicion for empyema and lung abscess. A case-control study of children hospitalised in the north east of England with clinical and radiological features of pneumonia revealed that empyema was evident in 25%.37 In empyema, effusions are initially exudative and become fibro-purulent, loculated, and infected without treatment. Ongoing fibroblastic growth causes formation of a thick peel over the visceral pleura, preventing lung expansion.
Other complications include necrotising pneumonia, systemic sepsis, haemolytic uraemic syndrome, and bronchiectasis following severe or complicated CAP. Offer secondary care referral to those with suspected complications.
What follow-up is required?
Follow-up is not routinely needed in children who recover fully without complications. Children who do not improve in 48-72 hours after starting treatment need reassessment, which can be in the community. Children who have lobar collapse, round pneumonia, or complications of CAP on radiography require follow-up as an outpatient at six to eight weeks with a repeat x ray and clinical assessment.
Reducing CAP incidence
Various public health measures reduce CAP incidence. The current UK vaccination schedule involves doses of pneumococcal conjugate vaccine (PCV) at 2, 4, and 12 months old. Haemophilus influenzae type B (Hib) vaccination is given at 2, 3, and 4 months with a booster at 1 year.38 An annual influenza vaccine is given to children between 2 and 8 years old every September, including children in school years 1, 2, and 3.38 Additional pneumococcal, and in some cases influenza, vaccination is provided for high risk children with asplenia or splenic dysfunction, cochlear implants (due to the meningitis risk), chronic disease, complement disorders, and immunosuppression.3839
PCV7 protects against seven pneumococccal serotypes: 4, 6B, 9V, 14, 18C, 19F, and 23F. At the time of its introduction to the UK vaccination schedule in 2006, these serotypes accounted for up to 90% of invasive pneumococcal disease in northern America and substantially fewer, up to 15%, of European cases.40 PCV13 was introduced into the UK schedule in 2010, providing additional cover for serotypes 1, 3, 4, 5 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
Globally, the WHO recommended routine Hib and PCV vaccination in 2006 and 2007 respectively. By 2016, 98% of countries had introduced Hib into their routine schedule and 68% had introduced PCV.41 Comparison of different PCV vaccination schedules has shown a marginal seropositivity benefit in those vaccinated with a primary course of three vaccines versus two, without any obvious clinical benefit.42
PCV implementation has reduced CAP incidence, admission rates, invasive pneumococcal disease, and radiologically confirmed pneumonia in both developed and low income settings.4344454647 PCV13 introduction has prevented infection by resistant pneumococcal strains including serotype 19A. Hib vaccination has reduced pneumonia rates in the developing world and the UK.4849 Canadian data suggest that routine influenza vaccination reduces mortality in all ages and emergency department attendances.50
Additional educational resources
Resources for clinicians
Harris M, Clark J, Coote N, et al; British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011;66(suppl 2):ii1-23. doi:10.1136/thoraxjnl-2011-200598
World Health Organization. Revised WHO classification and treatment of pneumonia in children at health facilities: evidence summaries. 2014. http://apps.who.int/iris/bitstream/10665/137319/1/9789241507813_eng.pdf
Balfour-Lynn IM, Abrahamson E, Cohen G, et al; Paediatric Pleural Diseases Subcommittee of the BTS Standards of Care Committee. BTS guidelines for the management of pleural infection in children. Thorax 2005;60(suppl 1):i1-21. doi:10.1136/thx.2004.030676
Public Health England. The complete routine immunisation schedule. 2016. www.gov.uk/government/publications/the-complete-routine-immunisation-schedule
Resources for patients
NHS Choices. Pneumonia. www.nhs.uk/Conditions/Pneumonia/Pages/Introduction.aspx
NHS Choices. Vaccinations: When to have vaccinations. www.nhs.uk/conditions/vaccinations/pages/vaccination-schedule-age-checklist.aspx
How patients were involved in this article
The BMJ did not ask the authors to involve patients in the creation of this article.
Competing interests: We have read and understood the BMJ Group policy on declaration of interests and have no relevant interests to declare.
Provenance and peer review: Commissioned; externally peer reviewed.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial